Home › Research › Treatments
The Cost of Alzheimer Drug Treatment
Guirgis Hely M. Zenodo (CERN European Organization for Nuclear Research), 2026-01-17
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Yearly costs of evolocumab were $6,840. Donanemab was more expensive at $32,000. Pembrolizumab was $160,00, durvalumab $115,000,Osimertinib $100,000, semaglutide $12,000, proposed 9-month ivonescimab $188,000. Donanemab $32,000 yearly cost was higher than evolocumab at $6,840. Both drugs were reasonably priced as compared with otherclasses. Considering longevity, the overall worldwide Alzheimerfuture management would be too costly to be affordable.
What this study adds
Evidence grade: Low
This cost analysis reports that donanemab costs $32,000 yearly, higher than evolocumab at $6,840 but reasonably priced compared with other drug classes. It concludes that considering longevity, overall worldwide Alzheimer future management would be too costly to be affordable.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Guirgis Hely, M. (2026). The Cost of Alzheimer Drug Treatment. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.18531026
Vancouver
Guirgis Hely M. The Cost of Alzheimer Drug Treatment. Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.18531026.
BibTeX
@article{guirgishely2026-eb95fab7,
author = {Guirgis Hely, M.},
title = {{The Cost of Alzheimer Drug Treatment}},
journal = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2026},
doi = {10.5281/zenodo.18531026},
url = {https://doi.org/10.5281/zenodo.18531026}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Pembrolizumab was $160,00, durvalumab $115,000,Osimertinib $100,000, semaglutide $12,000, proposed 9-month ivonescimab $188,000.
- Donanemab $32,000 yearly cost was higher than evolocumab at $6,840.
- Both drugs were reasonably priced as compared with otherclasses.
- Considering longevity, the overall worldwide Alzheimerfuture management would be too costly to be affordable.
Why it matters
This cost analysis reports that donanemab costs $32,000 yearly, higher than evolocumab at $6,840 but reasonably priced compared with other drug classes. It concludes that considering longevity, overall worldwide Alzheimer future management would be too costly to be affordable.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 29/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record and senior author's track record, so those were left out: it earned 27 of the 92 points we could judge it on, which is 29 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Zenodo (CERN European Organization for Nuclear Research)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Guirgis Hely M holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 1 / 3 | University of California, Irvine: institution h-index 1,195 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 27 / 92 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 27 of the 92 points we could judge it on is 29 out of 100. |
| Total | 29 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.5281/zenodo.18531026
- Original source →
- Free full text: Zenodo (CERN European Organization for Nuclear Research) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
196 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.